Genomic Newborn Screening for Pediatric Cancer Predisposition Syndromes: A Holistic Approach

As next-generation sequencing (NGS) has become more widely used, germline and rare genetic variations responsible for inherited illnesses, including cancer predisposition syndromes (CPSs) that account for up to 10% of childhood malignancies, have been found. The CPSs are a group of germline genetic disorders that have been identified as risk factors for pediatric cancer development. Excluding a few “classic” CPSs, there is no agreement regarding when and how to conduct germline genetic diagnostic studies in children with cancer due to the constant evolution of knowledge in NGS technologies. Various clinical screening tools have been suggested to aid in the identification of individuals who are at greater risk, using diverse strategies and with varied outcomes. We present here an overview of the primary clinical and molecular characteristics of various CPSs and summarize the existing clinical genomics data on the prevalence of CPSs in pediatric cancer patients. Additionally, we discuss several ethical issues, challenges, limitations, cost-effectiveness, and integration of genomic newborn screening for CPSs into a healthcare system. Furthermore, we assess the effectiveness of commonly utilized decision-support tools in identifying patients who may benefit from genetic counseling and/or direct genetic testing. This investigation highlights a tailored and systematic approach utilizing medical newborn screening tools such as the genome sequencing of high-risk newborns for CPSs, which could be a practical and cost-effective strategy in pediatric cancer care.

[1]  S. Gaikwad,et al.  Newborn Screening in Developing Countries: The Need of the Hour , 2024, Cureus.

[2]  A. Astegno,et al.  Biochemical and structural impact of two novel missense mutations in cystathionine beta-synthase gene associated with homocystinuria. , 2024, The Biochemical journal.

[3]  Y. Bombard,et al.  Prospective cohort study of genomic newborn screening: BabyScreen+ pilot study protocol. , 2024, BMJ open.

[4]  K. Cole,et al.  Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study. , 2024, The Lancet. Oncology.

[5]  R. Carrozzo,et al.  Case report: A safeguard in the sea of variants of uncertain significance: a case study on child with high risk neuroblastoma and acute myeloid leukemia , 2024, Frontiers in oncology.

[6]  B. Crompton,et al.  Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children’s Oncology Group AREN18B5-Q , 2023, Nature communications.

[7]  U. AlAlami,et al.  Studying carrier frequency of spinal muscular atrophy in the State of Qatar and comparison to other ethnic groups: Pilot study , 2023, Molecular genetics & genomic medicine.

[8]  Anne L. Ersig,et al.  Call to Action for Advancing Equitable Genomic Newborn Screening , 2023, Public Health Genomics.

[9]  Yuanyuan Gu,et al.  Genome Sequencing for Newborn Screening-An Effective Approach for Tackling Rare Diseases. , 2023, JAMA network open.

[10]  Zhiyu Peng,et al.  Genomic Sequencing as a First-Tier Screening Test and Outcomes of Newborn Screening , 2023, JAMA network open.

[11]  Meshal Almutairi,et al.  Knowledge of Cancer Genetics and the Importance of Genetic Testing: A Public Health Study , 2023, Cureus.

[12]  J. Savulescu,et al.  Are We Ready for Whole Population Genomic Sequencing of Asymptomatic Newborns? , 2023, Pharmacogenomics and personalized medicine.

[13]  R. Scott,et al.  Genomic newborn screening for rare diseases , 2023, Nature Reviews Genetics.

[14]  A. Naeem,et al.  MDM2- an indispensable player in tumorigenesis , 2023, Molecular Biology Reports.

[15]  E. Schröck,et al.  A clinical screening tool to detect genetic cancer predisposition in pediatric oncology shows high sensitivity but can miss a substantial percentage of affected children. , 2023, Genetics in medicine : official journal of the American College of Medical Genetics.

[16]  H. Pederson,et al.  Longitudinal Analysis of Cancer Risk in Children and Adults With Germline PTEN Variants , 2023, JAMA network open.

[17]  S. Behjati,et al.  Diagnostic classification of childhood cancer using multiscale transcriptomics , 2023, Nature Medicine.

[18]  A. Patiño-García,et al.  Identification of germline cancer predisposition variants in pediatric sarcoma patients from somatic tumor testing , 2023, Scientific Reports.

[19]  Saskia M. J. Hopman,et al.  Assessment of Cancer Predisposition Syndromes in a National Cohort of Children With a Neoplasm , 2023, JAMA network open.

[20]  P. Rahimi,et al.  Biomarkers and Corresponding Biosensors for Childhood Cancer Diagnostics , 2023, Sensors.

[21]  Arun K. Ramani,et al.  The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations , 2022, Nature Cancer.

[22]  M. Cazzola Risk stratifying MDS in the time of precision medicine. , 2022, Hematology. American Society of Hematology. Education Program.

[23]  K. Wimmer,et al.  High yield of surveillance in patients diagnosed with constitutional mismatch repair deficiency , 2022, Journal of Medical Genetics.

[24]  D. Malkin,et al.  Genetic predisposition to cancers in children and adolescents , 2022, Current opinion in pediatrics.

[25]  D. Vears,et al.  Australian healthcare professionals' perspectives on the ethical and practical issues associated with genomic newborn screening , 2022, Journal of genetic counseling.

[26]  E. Shagimardanova,et al.  Application of Multigene Panels Testing for Hereditary Cancer Syndromes , 2022, Biology.

[27]  Erin L Marcotte,et al.  Landscape of germline cancer predisposition mutations testing and management in pediatrics: Implications for research and clinical care , 2022, Frontiers in Pediatrics.

[28]  Shan Jiang A Scoping Review of Global Guidelines for the Disclosure of Secondary Genomic Findings to Inform the Establishment of Guidelines in China , 2022, China CDC weekly.

[29]  A. Biffi,et al.  Diagnostic Strategies and Algorithms for Investigating Cancer Predisposition Syndromes in Children Presenting with Malignancy , 2022, Cancers.

[30]  H. Okkels,et al.  Genetic predisposition & evolutionary traces of pediatric cancer risk: A prospective 5-year population-based genome sequencing study of children with CNS tumors. , 2022, Neuro-oncology.

[31]  R. Howell,et al.  The Progress and Future of US Newborn Screening , 2022, International journal of neonatal screening.

[32]  R. Scott,et al.  Newborn Screening by Genomic Sequencing: Opportunities and Challenges , 2022, International journal of neonatal screening.

[33]  W. Rashed,et al.  Germline De Novo Mutations as a Cause of Childhood Cancer. , 2022, JCO precision oncology.

[34]  S. Mueller,et al.  TBIO-12. Screening for Cancer Predisposition Syndromes in Pediatric Neuro-Oncology Patients: a Single Institution Experience , 2022, Neuro-Oncology.

[35]  P. Kolatkar,et al.  Pyridoxine non-responsive R336C mutation alters the molecular properties of cystathionine beta-synthase leading to severe homocystinuria phenotype. , 2022, Biochimica et biophysica acta. General subjects.

[36]  D. Parsons,et al.  Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute–Children's Oncology Group Pediatric MATCH Trial , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  N. André,et al.  The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies , 2022, Cancer discovery.

[38]  D. Ritter,et al.  Evolution of germline TP53 variant classification in children with cancer. , 2022, Cancer genetics.

[39]  L. Walker,et al.  Paediatric cancer predisposition syndromes in the genomic age , 2022, Paediatrics and Child Health.

[40]  M. Nelen,et al.  Towards Next-Generation Sequencing (NGS)-Based Newborn Screening: A Technical Study to Prepare for the Challenges Ahead , 2022, International journal of neonatal screening.

[41]  Zhengyan Zhao,et al.  Application of a next-generation sequencing (NGS) panel in newborn screening efficiently identifies inborn disorders of neonates , 2022, Orphanet Journal of Rare Diseases.

[42]  R. Grubs,et al.  Evaluation of barriers to referral for cancer predisposition syndromes in pediatric oncology patients in the United States , 2022, Journal of genetic counseling.

[43]  Alicia R. Martin,et al.  Diversity in Genomic Studies: A Roadmap to Address the Imbalance , 2022, Nature Medicine.

[44]  S. Kingsmore,et al.  Cost Efficacy of Rapid Whole Genome Sequencing in the Pediatric Intensive Care Unit , 2022, Frontiers in Pediatrics.

[45]  J. Mezey,et al.  The QChip1 knowledgebase and microarray for precision medicine in Qatar , 2022, NPJ genomic medicine.

[46]  N. Mahlaoui,et al.  Newborn screening as a fully integrated system to stimulate equity in neonatal screening in Europe , 2022, The Lancet regional health. Europe.

[47]  Christine Cahaney,et al.  Role of Precision Medicine in Pediatric Oncology. , 2022, Pediatric annals.

[48]  S. MacFarland,et al.  Childhood Cancer Predisposition: An Overview for the General Pediatrician. , 2022, Pediatric annals.

[49]  Kathleen F. Mittendorf,et al.  Systemic Barriers to Risk-Reducing Interventions for Hereditary Cancer Syndromes: Implications for Health Care Inequities. , 2021, JCO precision oncology.

[50]  Katherine M. Tucker,et al.  Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. , 2021, JAMA oncology.

[51]  J. Takita Molecular Basis and Clinical Features of Neuroblastoma , 2021, JMA Journal.

[52]  P. Nathan,et al.  Utility of a Cancer Predisposition Screening Tool for Predicting Subsequent Malignant Neoplasms in Childhood Cancer Survivors , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  David C. Jones,et al.  The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets , 2021, Cancer discovery.

[54]  Aman N. Patel,et al.  Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing , 2021, Cancer discovery.

[55]  Aashish N. Adhikari,et al.  The Use of Whole Genome and Exome Sequencing for Newborn Screening: Challenges and Opportunities for Population Health , 2021, Frontiers in Pediatrics.

[56]  D. Amor,et al.  Principles of Genomic Newborn Screening Programs , 2021, JAMA network open.

[57]  D. Koirala,et al.  Symptomatic familial adenomatous polyposis in an adolescent: A case report , 2021, International journal of surgery case reports.

[58]  R. Kuiper,et al.  Selection criteria for assembling a pediatric cancer predisposition syndrome gene panel , 2021, Familial Cancer.

[59]  S. Pfister,et al.  Cancer predisposition in pediatric neuro-oncology-practical approaches and ethical considerations. , 2021, Neuro-oncology practice.

[60]  T. Battelino,et al.  Next-Generation Sequencing in Newborn Screening: A Review of Current State , 2021, Frontiers in Genetics.

[61]  C. Tebbi Etiology of Acute Leukemia: A Review , 2021, Cancers.

[62]  A. Borkhardt,et al.  Comprehensive germline-genomic and clinical profiling in 160 unselected children and adolescents with cancer , 2021, European Journal of Human Genetics.

[63]  M. Gee,et al.  Screening of cancer predisposition syndromes , 2021, Pediatric Radiology.

[64]  Matthew S. Lebo,et al.  Discordant results between conventional newborn screening and genomic sequencing in the BabySeq Project , 2021, Genetics in Medicine.

[65]  Christine Y. Lu,et al.  Universal newborn genetic screening for pediatric cancer predisposition syndromes: model-based insights , 2021, Genetics in Medicine.

[66]  Floor A. M. Postema,et al.  Clinical value of a screening tool for tumor predisposition syndromes in childhood cancer patients (TuPS): a prospective, observational, multi-center study , 2021, Familial Cancer.

[67]  N. Schultz,et al.  Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors , 2021, Nature Cancer.

[68]  S. Behjati,et al.  Predisposition to cancer in children and adolescents. , 2021, The Lancet. Child & adolescent health.

[69]  J. Christodoulou,et al.  Newborn bloodspot screening in the time of COVID-19 , 2021, Genetics in Medicine.

[70]  N. Tommerup,et al.  Nationwide germline whole genome sequencing of 198 consecutive pediatric cancer patients reveals a high incidence of cancer prone syndromes , 2020, PLoS genetics.

[71]  Borbala Mifsud,et al.  THE FUTURE OF MEDICINE, healthcare innovation through precision medicine: policy case study of Qatar , 2020, Life sciences, society and policy.

[72]  M. Qoronfleh,et al.  Pathway to excellence in cancer care: learning from Qatar's experience , 2020 .

[73]  A. Iolascon,et al.  Genetic Predisposition to Solid Pediatric Cancers , 2020, Frontiers in Oncology.

[74]  M. Cornel,et al.  Neonatal and carrier screening for rare diseases: how innovation challenges screening criteria worldwide , 2020, Journal of Community Genetics.

[75]  M. Durkin,et al.  Translating Molecular Technologies into Routine Newborn Screening Practice , 2020, International journal of neonatal screening.

[76]  David M. Thomas,et al.  Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer , 2020, Nature medicine.

[77]  L. Mirabello,et al.  Nearly Half of TP53 Germline Variants Predicted To Be Pathogenic in Patients With Osteosarcoma Are De Novo: A Report From the Children's Oncology Group. , 2020, JCO precision oncology.

[78]  N. J. Gillespie,et al.  Genitourinary manifestations of hereditary cancer predisposition syndromes in children , 2020, Translational andrology and urology.

[79]  Muneer H Albagshi,et al.  Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency Among Children in Eastern Saudi Arabia , 2020, Cureus.

[80]  E. Langfelder-Schwind,et al.  Bridging the Gap between Scientific Advancement and Real-World Application: Pediatric Genetic Counseling for Common Syndromes and Single-Gene Disorders. , 2020, Cold Spring Harbor perspectives in medicine.

[81]  V. Nagy,et al.  Genetic predisposition in pediatric oncology , 2020, Medicine and pharmacy reports.

[82]  Aman N. Patel,et al.  St. Jude Cloud—a Pediatric Cancer Genomic Data Sharing Ecosystem , 2020, bioRxiv.

[83]  Y. Bombard,et al.  Health-care practitioners’ preferences for the return of secondary findings from next-generation sequencing: a discrete choice experiment , 2020, Genetics in Medicine.

[84]  Aashish N. Adhikari,et al.  The role of exome sequencing in newborn screening for inborn errors of metabolism , 2020, Nature Medicine.

[85]  S. J. Henley,et al.  Pediatric cancer mortality and survival in the United States, 2001‐2016 , 2020, Cancer.

[86]  F. Cheng,et al.  Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors , 2020, Nature Communications.

[87]  S. Namayandeh,et al.  GLOBAL Leukemia in Children 0-14 Statistics 2018, Incidence and Mortality and Human Development Index (HDI): GLOBOCAN Sources and Methods , 2020, Asian Pacific journal of cancer prevention : APJCP.

[88]  David M. Thomas,et al.  Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. , 2020, JAMA oncology.

[89]  A. Goel,et al.  Mosaicism in Patients With Colorectal Cancer or Polyposis Syndromes: a Systematic Review. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[90]  P. Schielen,et al.  Introducing and Expanding Newborn Screening in the MENA Region , 2020, International journal of neonatal screening.

[91]  E. Steliarova-Foucher,et al.  Childhood cancer: Estimating regional and global incidence. , 2020, Cancer epidemiology.

[92]  J. Stoll,et al.  Risk Assessment and Genetic Testing for Inherited Gastrointestinal Syndromes. , 2019, Gastroenterology & hepatology.

[93]  P. Easterbrook,et al.  Hepatitis B virus infection in children and adolescents. , 2019, The lancet. Gastroenterology & hepatology.

[94]  Gheyath K Nasrallah,et al.  Natural history, with clinical, biochemical, and molecular characterization of classical homocystinuria in the Qatari population , 2019, Journal of inherited metabolic disease.

[95]  P. Hainaut,et al.  Cost‐effectiveness of early cancer surveillance for patients with Li–Fraumeni syndrome , 2019, Pediatric blood & cancer.

[96]  J. Biegel,et al.  The genomic landscape of pediatric cancers: Implications for diagnosis and treatment , 2019, Science.

[97]  S. Rednam Updates on progress in cancer screening for children with hereditary cancer predisposition syndromes , 2019, Current opinion in pediatrics.

[98]  N. Hawkes Cancer survival data emphasise importance of early diagnosis , 2019, British Medical Journal.

[99]  J. Wise Genome sequencing of children promises a new era in oncology , 2019, British Medical Journal.

[100]  Matthew S. Lebo,et al.  Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project. , 2019, American journal of human genetics.

[101]  P. Carter,et al.  The Major Causes of Death in Children and Adolescents in the United States. , 2018, The New England journal of medicine.

[102]  Gheyath K Nasrallah,et al.  In silico and in vivo models for Qatari‐specific classical homocystinuria as basis for development of novel therapies , 2018, Human mutation.

[103]  A. Loh,et al.  Clinical relevance of screening checklists for detecting cancer predisposition syndromes in Asian childhood tumours , 2018, npj Genomic Medicine.

[104]  R. Siebert,et al.  Family-based germline sequencing in children with cancer , 2018, Oncogene.

[105]  B. Solomon,et al.  Clinical genetics and genomic medicine in Qatar , 2018, Molecular genetics & genomic medicine.

[106]  W. Foulkes,et al.  Retrospective evaluation of a decision‐support algorithm (MIPOGG) for genetic referrals for children with neuroblastic tumors , 2018, Pediatric blood & cancer.

[107]  M. Abrar,et al.  Prevalence of hereditary cancer susceptibility syndromes in children with cancer in a highly consanguineous population. , 2018, Cancer epidemiology.

[108]  R. Green,et al.  The BabySeq project: implementing genomic sequencing in newborns , 2018, BMC Pediatrics.

[109]  Jeremy Michelson My Diagnostic Odyssey-A Call to Expand Access to Genomic Testing for the Next Generation. , 2018, The Hastings Center report.

[110]  E. Parens,et al.  Sequencing Newborns: A Call for Nuanced Use of Genomic Technologies. , 2018, The Hastings Center report.

[111]  Michael C. Heinold,et al.  The landscape of genomic alterations across childhood cancers , 2018, Nature.

[112]  Xin Zhou,et al.  Pan-cancer genome and transcriptome analyses of 1,699 pediatric leukemias and solid tumors , 2018, Nature.

[113]  Z. Memish,et al.  Distribution of hemoglobinopathy disorders in Saudi Arabia based on data from the premarital screening and genetic counseling program, 2011–2015 , 2017, Journal of epidemiology and global health.

[114]  L. Guerrini-Rousseau,et al.  Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome , 2017, Journal of Medical Genetics.

[115]  A. Shimamura,et al.  Genetic predisposition to hematologic malignancies: management and surveillance. , 2017, Blood.

[116]  H. Rehm A new era in the interpretation of human genomic variation , 2017, Genetics in Medicine.

[117]  W. Foulkes,et al.  Retinoblastoma and Neuroblastoma Predisposition and Surveillance , 2017, Clinical Cancer Research.

[118]  H. Blom,et al.  Cysteamine revisited: repair of arginine to cysteine mutations , 2017, Journal of Inherited Metabolic Disease.

[119]  Eva Steliarova-Foucher,et al.  International incidence of childhood cancer, 2001–10: a population-based registry study , 2017, The Lancet. Oncology.

[120]  S. Plon,et al.  Pediatric Cancer Predisposition and Surveillance: An Overview, and a Tribute to Alfred G. Knudson Jr , 2017, Clinical Cancer Research.

[121]  W. Chung,et al.  Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients , 2017, Journal of Genetic Counseling.

[122]  Floor A. M. Postema,et al.  Validation of a clinical screening instrument for tumour predisposition syndromes in patients with childhood cancer (TuPS): protocol for a prospective, observational, multicentre study , 2017, BMJ Open.

[123]  Stuart J. Andrews,et al.  Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations , 2016, Genome Medicine.

[124]  P. Rosenberg,et al.  Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li‐Fraumeni syndrome cohort , 2016, Cancer.

[125]  M. Szego,et al.  Parents perspectives on whole genome sequencing for their children: qualified enthusiasm? , 2016, Journal of Medical Ethics.

[126]  J. Shendure,et al.  The power of multiplexed functional analysis of genetic variants , 2016, Nature Protocols.

[127]  R. Gibbs,et al.  Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.

[128]  Julie O. Culver,et al.  Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohort. , 2016, Cancer genetics.

[129]  R. Kuiper,et al.  Recognition of genetic predisposition in pediatric cancer patients: An easy-to-use selection tool. , 2016, European journal of medical genetics.

[130]  J. Botkin,et al.  Whole Genome Sequencing and Newborn Screening , 2016, Current Genetic Medicine Reports.

[131]  A. McGuire,et al.  Potential Psychosocial Risks of Sequencing Newborns , 2016, Pediatrics.

[132]  Wendy K Chung,et al.  Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing , 2015, Genetics in Medicine.

[133]  Li Ding,et al.  Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.

[134]  G. Leverger,et al.  Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  Nallasivam Palanisamy,et al.  Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. , 2015, JAMA.

[136]  F. Saletta,et al.  Genetic causes of cancer predisposition in children and adolescents. , 2015, Translational pediatrics.

[137]  J. Loeber,et al.  Current status of newborn screening worldwide: 2015. , 2015, Seminars in perinatology.

[138]  J. Shohet,et al.  Neuroblastoma: molecular pathogenesis and therapy. , 2015, Annual review of medicine.

[139]  Magalie S Leduc,et al.  Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.

[140]  B. Monk,et al.  Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. , 2014, Gynecologic oncology.

[141]  T. Sokolsky,et al.  Development of DNA Confirmatory and High-Risk Diagnostic Testing for Newborns Using Targeted Next-Generation DNA Sequencing , 2014, Genetics in Medicine.

[142]  Natasha F Bonhomme,et al.  Newborn screening: adapting to advancements in whole-genome sequencing. , 2014, Genetic testing and molecular biomarkers.

[143]  F. Westermann,et al.  A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies , 2014, Oncogene.

[144]  N. Rahman,et al.  Mainstreaming genetic testing of cancer predisposition genes. , 2014, Clinical medicine.

[145]  S. Berry Newborn screening. , 2014, Clinics in perinatology.

[146]  V. Mitev,et al.  APC promoter 1B deletion in familial polyposis—implications for mutation‐negative families , 2014, Clinical genetics.

[147]  Heather L. Mulder,et al.  The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes , 2014, Nature Communications.

[148]  Wylie Burke,et al.  Genetic Tests: Clinical Validity and Clinical Utility , 2014, Current protocols in human genetics.

[149]  H. Levy Newborn screening: the genomic challenge , 2014, Molecular genetics & genomic medicine.

[150]  A. Bredenoord,et al.  The Right to an Open Future Concerning Genetic Information , 2014, The American journal of bioethics : AJOB.

[151]  F. Couch,et al.  Functional Assays for Analysis of Variants of Uncertain Significance in BRCA2 , 2014, Human mutation.

[152]  Evan E Eichler,et al.  Properties and rates of germline mutations in humans. , 2013, Trends in genetics : TIG.

[153]  M. Pourfarzam,et al.  Newborn Screening for inherited metabolic disorders; news and views , 2013, Journal of Research in Medical Sciences.

[154]  Elliot Stieglitz,et al.  Genetic predispositions to childhood leukemia , 2013, Therapeutic advances in hematology.

[155]  H. Saal,et al.  Ethical and Policy Issues in Genetic Testing and Screening of Children , 2013, Pediatrics.

[156]  F. Couch,et al.  A guide for functional analysis of BRCA1 variants of uncertain significance , 2012, Human mutation.

[157]  Zahra Saberi,et al.  Neurofibromatosis type I (von Recklinghausen's disease): A family case report and literature review , 2012, Dental research journal.

[158]  S. Steinberg,et al.  Rate of de novo mutations, father’s age, and disease risk , 2012, Nature.

[159]  Li Ding,et al.  The Pediatric Cancer Genome Project , 2012, Nature Genetics.

[160]  M. Järvelin,et al.  Meta-analysis of paternal age and schizophrenia risk in male versus female offspring. , 2011, Schizophrenia bulletin.

[161]  J. Shendure,et al.  Needles in stacks of needles: finding disease-causal variants in a wealth of genomic data , 2011, Nature Reviews Genetics.

[162]  Ching-Hon Pui,et al.  Challenging issues in pediatric oncology , 2011, Nature Reviews Clinical Oncology.

[163]  P. Babyn,et al.  Imaging of cancer predisposition syndromes in children. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[164]  A. Shlien,et al.  Copy number variations and cancer susceptibility , 2010, Current opinion in oncology.

[165]  D. Bercovich,et al.  Familial adenomatous polyposis , 2009, Orphanet journal of rare diseases.

[166]  G. Draper,et al.  Non-ocular tumours following retinoblastoma in Great Britain 1951 to 2004 , 2009, British Journal of Ophthalmology.

[167]  D. Marsden,et al.  Newborn Screening , 2009, Critical reviews in clinical laboratory sciences.

[168]  Uri Tabori,et al.  Excessive genomic DNA copy number variation in the Li–Fraumeni cancer predisposition syndrome , 2008, Proceedings of the National Academy of Sciences.

[169]  Dieter Niederacher,et al.  Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. , 2008, American journal of human genetics.

[170]  D. Malkin,et al.  Hereditary cancer predisposition in children: Genetic basis and clinical implications , 2006, International journal of cancer.

[171]  K K Matthay,et al.  Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[172]  K. Offit,et al.  Hereditary cancer predisposition syndromes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[173]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[174]  Edwin W. Naylor,et al.  Effect of Expanded Newborn Screening for Biochemical Genetic Disorders on Child Outcomes and Parental Stress , 2003 .

[175]  S. Pakakasama,et al.  Genetic predisposition and screening in pediatric cancer. , 2002, Pediatric clinics of North America.

[176]  B. Therrell U.S. newborn screening policy dilemmas for the twenty-first century. , 2001, Molecular genetics and metabolism.

[177]  W F Bodmer,et al.  The ABC of APC. , 2001, Human molecular genetics.

[178]  M. Kambouris,et al.  Heterogeneity of the cystic fibrosis phenotype in a large kindred family in Qatar with cystic fibrosis mutation (I1234V). , 2001, Journal of tropical pediatrics.

[179]  B. Hankey,et al.  The surveillance, epidemiology, and end results program: a national resource. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[180]  D. Gutmann,et al.  Loss of neurofibromatosis type I (NFI) gene expression in pheochromocytomas from patients without NFI , 1994, Genes, chromosomes & cancer.

[181]  G. Brodeur The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes. , 1994, The New England journal of medicine.

[182]  J. Akatsuka,et al.  Neurofibromatosis type 1 and childhood cancer , 1993, Cancer.

[183]  B. Gallie,et al.  A simplified scheme for genetic counseling in retinoblastoma. , 1987, Journal of pediatric ophthalmology and strabismus.

[184]  Stephen H. Friend,et al.  A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma , 1986, Nature.

[185]  D. Gutmann,et al.  Optic Pathway Gliomas in Neurofibromatosis Type 1 , 2018, Journal of child neurology.

[186]  Meghan C Towne,et al.  Beta-Ketothiolase Deficiency Presenting with Metabolic Stroke After a Normal Newborn Screen in Two Individuals. , 2018, JIMD reports.

[187]  Allison P. Heath,et al.  Data Commons to Support Pediatric Cancer Research. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[188]  J. Bohlius,et al.  HIV-associated malignancies in children , 2017, Current opinion in HIV and AIDS.

[189]  C. Isaacs,et al.  How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[190]  R. Guthrie,et al.  The introduction of newborn screening for phenylketonuria , 2009, European Journal of Pediatrics.

[191]  Newborn screening: toward a uniform screening panel and system. , 2006, Genetics in medicine : official journal of the American College of Medical Genetics.

[192]  P. Kleihues,et al.  Tumors associated with p53 germline mutations: a synopsis of 91 families. , 1997, The American journal of pathology.

[193]  C. Pratt,et al.  Neurofibromatosis type I and malignancy: review of 32 pediatric cases treated at a single institution. , 1994, Medical and pediatric oncology.

[194]  M. Bisgaard,et al.  Familial adenomatous polyposis (FAP): Frequency, penetrance, and mutation rate , 1994, Human mutation.